| abstract |
Use of a combination of a single progestogen selected from the group consisting of progesterone, chlormadinone acetate, norethistrone acetate, cyproterone acetate, desogestrel, levonorgestrel, antigestagens, progestin or antigestagen horinone analogs, and hormone compounds which rapidly degrade at least one progestogen after ingestion and a single estrogen selected from synthetic estrogen, ethinylestradiol at a daily dose of 1 - 20 μg, mestranol or a hormone compound which rapidly splits off at least one synthetic estrogen after ingestion and biogenic estrogens, namely estradiol estriol, estrone, estrane or a hormone compound which rapidly eliminates at least one biogenic effluent after ingestion, as sole hormonal agents for the preparation of an agent for and / or prophylaxis of mammary tumor by uninterrupted oral, transdermal or depot administration. |